Project Grant R44TR005945
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $865K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
- The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
- The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded a $349,746 Project Grant to Cisterna Biologics, Inc., a biotechnology company based in Oceanside, California. The goal of this 1-year Phase I SBIR grant is to develop an innovative platform for synthesizing high-quality, purified mRNA with minimal contaminants such as double-stranded RNA, long RNA, and short truncated RNA. These impurities can provoke immune responses and...
- This Project Grant award of $349,909.00 from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) will support the development of Nanoengineering Corporation's viral vector sizing tool to improve gene therapy analytics and reduce drug development costs. The funding will enable the commercialization of Nanoengineering's proprietary electrospray differential mobility analysis (ES-DMA) method, which can quickly and accurately measure the size of virus capsids at an...
- This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $1,050,276 Project Grant to Syntr Health Technologies, Inc. on September 25, 2025 under the CFDA 93.350 Federal Grant Program. This funding supports the development and automation of an FDA-cleared CD-microfluidic platform for rapid tissue microsizing. The platform technology can process a variety of tissue types, including cancer tumors and adipose tissue, to enable single-cell analysis and regenerative medical...
- The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
- This $419,398 Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS) CFDA Program 93.350, is supporting research to accelerate the development and delivery of oligonucleotide therapeutics (ONTs). The project aims to address the key barrier of biological membrane permeability that limits the ability of large, charged ONT molecules to reach their therapeutic targets within cells. The research at the University of California, Irvine will explore novel...
- The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 Federal Grant Program, awarded a $294,541 Project Grant to Cellular Vehicles Inc. on June 1, 2024. The purpose of this award is to develop an automated system for producing and delivering cell-laden hydrogel therapies. The project aims to create a novel, standardized process for formulating, encapsulating, and directly injecting cell-laden hydrogels into diseased tissues. This is intended to improve the...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $1,077,369 Project Grant to Captis Diagnostics Inc. on March 11, 2025 to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for the rapid, efficient, and cost-effective isolation of extracellular vesicles (EVs) from non-invasive bodily fluids. The project, funded under NCATS' Federal Grant Program (CFDA 93.350), aims to unlock the potential of EVs in multi-omics-based disease molecular characterization...